GH
ADMS

GAM Holding’s Adamas Pharmaceuticals ADMS Stock Holding History

GAM Holding’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20,000
Closed -$350K – 986
2017
Q2 		$350K Hold
20,000
– – 0.01% 885
2017
Q1 		$350K Hold
20,000
– – 0.01% 879
2016
Q4 		$338K Hold
20,000
– – 0.01% 851
2016
Q3 		$328K Buy
+20,000
New +$304K 0.01% 804

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KA
Kerrisdale Advisers Miami, Florida $263M AUM 40.01% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

GAM Holding's ADMS Position: Q3 2017 in Review

GAM Holding sold out of Adamas Pharmaceuticals (ADMS) in Q3 2017, closing a stake of 20,000 shares — an estimated $350K sold.

GAM Holding first reported a position in ADMS in Q3 2016 and held it in 4 quarters. The position peaked at $350K in Q2 2017. 95 funds tracked by Wall St. Rank hold ADMS as of Q3 2017.

  • GAM Holding reported no remaining Adamas Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • GAM Holding sold 20,000 Adamas Pharmaceuticals shares in Q3 2017, an estimated $350K.
  • GAM Holding first reported a position in Adamas Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • GAM Holding's Adamas Pharmaceuticals position peaked at $350K in Q2 2017.
  • 95 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2017.

Based on GAM Holding's 13F filing for Q3 2017, filed 14 Nov 2017.